Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
688331.SSYANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary...
August 13, 2025Clinical Trials
Read more →